Nucleonics Inc.
This article was originally published in Start Up
Executive Summary
Nucleonics Inc. has turned to plasmid DNA delivery technology as an answer to the siRNA delivery challenge. The company believes this approach could be an effective mechanism for selectively targeting viruses, and offers significant advantages over other methods for generating a gene silencing response in targeted cells